Retinal pigment epithelial cell replacement therapy - Cell Cure Neurosciences

Drug Profile

Retinal pigment epithelial cell replacement therapy - Cell Cure Neurosciences

Alternative Names: OpRegen; OpRegen-Plus; OpRegen® RPE cells

Latest Information Update: 30 Sep 2015

Price : $50

At a glance

  • Originator Cell Cure Neurosciences
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Dry age-related macular degeneration

Most Recent Events

  • 28 Sep 2015 Retinal pigment epithelial cell replacement therapy receives Fast Track designation from the US FDA for Dry age-related macular degeneration [Intraocular,Injection]
  • 13 May 2015 Cell Cure Neurosciences receives grant from the Israel's Office of the Chief Scientist to support development of OpRegen®
  • 01 Apr 2015 Phase-I/II clinical trials in Dry age-related macular degeneration in Israel (Intraocular) (NCT02286089)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top